Rheumatoid arthritis is an autoimmune disease that primarily affects the limbs, but the pathogenic mechanism remains unclear. cd T cells, a T-cell subpopulation, are characterized by multiple biological functions and associated with a variety of diseases. This study investigated the antigen-presenting effects of cd T cells and their relationship with rheumatoid arthritis development. We found that Vc9Vd2 T cells (the predominant subtype of cd T cells in peripheral blood) were activated by isopentenyl pyrophosphate to continuously proliferate and differentiate into effector memory cells. The effector memory Vc9Vd2 T cells exhibited phenotypic characteristics of specific antigen-presenting cells, including high HLA-DR and CD80/86 expression. These Vc9Vd2 T cells could present soluble antigens and synthetic peptides to CD4
INTRODUCTION
Rheumatoid arthritis (RA) is a common and systemic autoimmune disease predominantly affecting the limbs. The prevalence of RA worldwide is 0.5%-1%, with 4 000 000 new cases reported every year. The development of RA is mediated by immune system dysfunction, although the exact pathogenic mechanisms remain unclear. In particular, the hypothesis that latent Epstein-Barr virus (EBV) in susceptible individuals with particular genetic backgrounds (e.g., HLA-DRB1*01 or HLA-DRB1*04) is repeatedly activated and leads to RA has been intensively studied. 1 Previous studies showed that there are close correlations between the HLA-DR4-positive genetic background and the occurrence and development of RA. [2] [3] [4] Additionally, studies on 'molecular mimicry' suggested that EBVgp110 has a common motif with HLA-DR4 and thus can induce and activate autoreactive T cells and cause a series of autoimmune responses and pathologic damage. 5 Although the roles of abnormal T/B cells in RA have been extensively investigated by a large number of researchers, 6 -10 a number of papers since the 1990s have revealed that cd T cells with abnormal functions exist in the joints and that these cells characteristically express HLA-DR, suggesting that these cd T cells may play unknown biological roles in RA. 11, 12 Recent studies also suggested that cd T cells are an important source of IL-17 and are involved in multiple diseases via their secretion of IL-17. [13] [14] [15] cd T cells, a small subpopulation of T cells, can be divided into several subtypes according to different combinations of the T-cell receptor (TCR) c-and d-chains, and they exhibit different biological characteristics because of the heterogeneity among the subtypes. [16] [17] [18] [19] The small number of cd T cells in peripheral blood makes them difficult to investigate. We have extensively studied a variety of ways to amplify cd T cells to study their differentiation and immunological functions. cd T cells are known to play important roles in infection, immunity, autoimmunity and tumor immunity [20] [21] [22] [23] [24] and therefore, to some extent, can be regarded as pluripotent cells. These cells are involved in various human diseases and have substantial clinical implications. Our study investigated the latent antigen-presenting function of cd T cells and their association with RA pathogenesis.
MATERIALS AND METHODS
Healthy donors and RA patients Peripheral blood samples were taken from healthy donors 20-25 years of age that met the following criteria: no flu symptoms (e.g., fever or cough); negative blood, urine and fecal examinations; no chronic diseases such as hypertension, diabetes, kidney disease, heart disease or liver diseases; and no medical history or family history of autoimmune diseases. RA patients were recruited from Guanghua Rheumatoid Arthritis Specialized Hospital (Shanghai, China) with the approval from the Independent Ethics Committee and signed the informed consent forms themselves. The selection criteria are listed in Table 1 .
Cell isolation and culture Density gradient centrifugation was used to isolate peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs). Magnetic-activated cell sorting was performed according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany) to isolate CD4
1 T cells and B cells from the PBMCs. Fluorescence-activated cell sorting (FACS) was used to isolate the Vc9Vd2 T cells. After the isolation of CD4 1 T and B cells from the PBMCs of healthy donors, the remaining PBMCs or other cell populations were diluted to 1310 6 cells/ml with RPMI-1640 containing 10% fetal bovine serum (FBS), isopentenylpyrophosphate (IPP, 2 mg/ml) and low concentrations (5 U/ml) of IL-2, IL-7, IL-15 and/or IL-23. The cells were then cultured in 24-well sterile plates (1 ml/well) in a saturated humid environment containing 5% CO 2 at 37 uC. Every 3 days, the cells were collected and labeled to detect their phenotypes, and half of the culture medium was exchanged. Vc9Vd2 T cells were sorted at appropriate time points. Flow cytometry Extracellular staining.
Flow cytometry was used to analyze the purity of the target cells after sorting by magnetic-activated cell sorting, the ratios of cd T cells in the peripheral blood and synovial fluid of healthy donors and RA patients, the distribution and subtypes of Vc9Vd2 T cells and the phenotypic changes of Vc9Vd2 T cells after IPP induction. After rinsing with phosphate-buffered saline (PBS), the cells (1310 6 ) were resuspended in PBS supplemented with 1% FBS that contained the following fluorescently labeled monoclonal antibodies or their isotype control antibodies: cd-TCR, d2-TCR, c9-TCR, CD3, CD8, CD27, CD45RA, CD45RO, CD69, CD80, CD86 and/or HLADR. After incubation at 4 uC in the dark for 30 min, the cells were rinsed twice with PBS, fixed with 300 ml of PBS plus 1% paraformaldehyde and detected using a flow cytometer (BD FACS Calibur; BD Biosciences, Bedford, MA, USA). The results were analyzed with the BD Cellquest software (BD Biosciences).
Intracellular staining. The cytokine secretion patterns of the Vc9Vd2 T cells were analyzed by flow cytometry. Cells were harvested (1310 6 ) before and after culturing and were rinsed with RPMI-1640. The cells were resuspended with 1 ml of RPMI-1640 culture medium containing 100 ng/ml phorbol 12-myristate 13-acetate, 0.75 mg/ml ionomycin and 1.5 ml/ml GolgiStop (BD Biosciences) and were cultured for 4 h. The cells were then rinsed with PBS plus 1% FBS, resuspended with 100 ml of PBS plus 1% FBS plus fluorescently labeled monoclonal antibodies against d2-TCR and c9-TCR or isotype control antibodies and stained extracellularly at 4 uC in the dark for 30 min. After two rinses with PBS plus 1% FBS, 250 ml of the fixative/membrane-rupturing buffer solution was added and mixed, and the cells were incubated at 4 uC in the dark for 20 min. After two more rinses with PBS plus 1% FBS, the cells were resuspended with 100 ml of PBS plus 1% FBS plus either fluorescently labeled monoclonal antibodies against IL-17 and interferon (IFN)-c or isotype control antibodies and incubated at 4 uC in the dark for 30 min. Finally, the cells were rinsed twice with PBS plus 1% FBS, fixed with PBS plus 1% paraformaldehyde and detected by the BD FACS Calibur. The results were analyzed with BD Cellquest software.
Peptides synthesis
We commissioned the GL Biochem Ltd (Shanghai, China) to synthesize the three following peptides:
. tetanus toxoid peptide (TTp) sequences: QYIKANSKFIGITE; . EBVgp110 sequences: CEQNQEQKRAAQRAA; . HLA-DR4 sequences: CKDLLEQKRAAVDTY.
Cellular proliferation
The 3 H-TdR method was used to test the antigen-presenting efficacies of the different subtypes of the Vc9Vd2 T cells from the peripheral blood of healthy donors to purified protein derivative (PPD) and tetanus toxin (TT), the effector memory Vc9Vd2 T cells to synthetic peptides and the Vc9Vd2 T cells from RA patients to viral peptides and autoantigen peptides. B cells were used as controls.
Cytokine assays
The IL-17 and IFN-c levels in the supernatant of the cd T cell culture at different stages and in the serum and joint synovial fluid from RA patients were detected using a Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Statistical analysis
The paired Student's t-test (two-tailed) was used for the comparison of group values. The data were presented as mean6s.d. The significance was analyzed using Prism (GraphPad Software), and the values of P,0.05 were considered significant and are indicated in the corresponding figures (*, 0.01,P,0.05; **, 0.001,P,0.01; ***, P,0.001). Antigen-presenting effects of effector memory Vc9Vd2 T cells in RA CY Hu et al 248
RESULTS

Induction effect of IPP on cd T cells
Previous studies have reported that cd T cells can directly recognize some irregular antigen ligands such as the phosphorylated metabolites of microbiological organisms and lipid antigens (e.g., IPP, HMBPP and BrHPP) via TCRs, 21, 25, 26 and could be activated directly without the assistance of antigen-presenting cells. Our results indicated that IPP was able to stimulate cd T cells to proliferate at a certain concentration range. Furthermore, IL-2 can stimulate the proliferation of cd T cells either alone or synergistically with IPP; the highest proliferation was seen when the cd T cells were cultured with 2 mg/ml IPP and 5 U/ml IL-2. Under the synergic effect of IPP and IL-2, cd T cells (primarily Vc9Vd2 T cells) can be selectively activated and stimulated to proliferate, resulting in an increased ratio of T lymphocytes to total PBMCs (Figure 1) . Additionally, we also used IL-7, IL-15, and IL-23 to culture the cd T cells but did not find a significant influence of these cytokines to affect the proliferation and differentiation potential of cd T cells.
While the Vc9Vd2 T cells from the peripheral blood continuously proliferated in the presence of IPP, most of the Vc9Vd2 T cells were activated and transformed into effector memory cells (TEM, CD45RA 2 CD27 2 ) (Figure 2a ). During the differentiation of Vc9Vd2 T cells to TEM, CD69 (a marker of activated cells) began to be expressed, and then HLA-DR and CD86 (molecules related to the professional antigen-presenting function) appeared on the cells surface (Figure 2b and c) . After induction and activation, Vc9Vd2 T cells exhibited the phenotypes of antigen-presenting cells (APCs) and acquired the potential to present antigens.
Antigen-presenting function of TEM Vc9Vd2 T cells Purified TEM Vc9Vd2 T cells with high levels of HLA-DR and CD86 and Vc9Vd2 T cells that were freshly isolated from the peripheral blood (non-effector memory type, non-TEM) were both treated with TT (10 ng/ml) for 24 h. The cells were exposed to c-rays (4000 rad) and were then cocultured with purified autogenous CD4 1 T cells (10 5 cells per well) at the best ratio. Non-TEM and TEM Vc9Vd2 T cells before and after irradiation were cultured alone and served as controls. The TEM Vc9Vd2 T cells had a stronger stimulating effect on the proliferation of the CD4 1 T cells, and this stimulation could be blocked by an anti-HLA-DR antibody (Figure 3a) , suggesting that the TEM Vc9Vd2 T cells may activate CD4
1 T cells and stimulate their proliferation through the exogenous antigen-presenting pathway. In the culture system with PPD (10 mg/ml), TEM Vc9Vd2 T cells showed a similar efficacy (Figure 3b ). Because both TT and PPD are soluble antigens, we used B cells as the positive control. After 7 days of coculture with B cells or TEM Vc9Vd2 T cells, the proliferation of CD4
1 T cells was detected using the 3 H-TdR method. We unexpectedly found that the TEM Vc9Vd2 T cells were more effective than the autogenous B cells to present the TT and PPD antigens (Figure 3c and d) . 
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Cytokine secretion patterns of TEM Vc9Vd2 T cells The cell's function is not only related to its surface molecules but also to the cytokines secreted to the extracellular space. After activation by IPP, Vc9Vd2 T cells underwent proliferation and had changes in their subtype. We also measured the patterns of cytokines in the Vc9Vd2 T cell culture suspensions at different time points by ELISA. The concentration of IL-17 increased with the increase in the percentage of Vc9Vd2 T cells, while IFN-c did not show any obvious changes (Figure 4a ). To understand whether the changes in IL-17 were directly related to the proliferation and differentiation of the Vc9Vd2 T cells, we measured the levels of IL-17 and IFN-c in the supernatant of the media used to culture the purified non-TEM and TEM Vc9Vd2 T cells from healthy donors (both stimulated with phorbol 12-myristate 13-acetate and ionomycin). The results indicated that during the IPP-stimulation of the Vc9Vd2 T cells, IFN-c was maintained at a high level (Figure 4a ), suggesting that all of the subtypes of Vc9Vd2 T cells could secrete IFNc. However, IL-17 increased with the differentiation of Vc9Vd2 T cells (Figure 4b ), suggesting that TEM Vc9Vd2 T cells have a stronger capacity to secrete IL-17. We then sorted pure non-TEM and TEM Vc9Vd2 T cells by FACS (Figure 4c ). The non-TEM Vc9Vd2 T cells mainly secreted IFN-c (Figure 4d ), and only a portion of them secreted IL-17 ( Figure 4e ). The secretion pattern of the TEM Vc9Vd2 T cells changed substantially; they secreted not only IFN-c but also high levels of IL-17 (Figure 4d and e) . Intracellular staining of Vc9Vd2 T cells revealed that both the non-TEM and TEM Vc9Vd2 T cells were able to secret IFN-c, but only the TEM cells secreted high levels of IL-17 ( Figure 4f) . Therefore, the Vc9Vd2 T cells that had different phenotypic characteristics and secretion patterns were likely to possess various immune functions. The research on the Vc9Vd2 T cells phenotypes and functions has provided a basis for further studies on the relationship between cd T cells and diseases such as RA and pulmonary tuberculosis.
Characteristics of cd T cells in RA patients
Several studies 11, 12 reported that cd T cells with abnormal functions existed in the joints of RA patients, although the immunopathological mechanism of RA is unclear. Therefore, we analyzed the phenotypes of cd T cells in the peripheral blood and synovial fluid of RA patients. We found that cd T cells in the synovial fluid were different from those in the peripheral blood because the ratio of cd T cells in the synovial fluid was significantly higher (about 20%) (Figure 5a ). Vc9Vd2 T cells were the predominant subpopulation of cd T cells in both the peripheral blood and also the synovial fluid from RA patients, and flow cytometry analyses indicated that the TEM Vc9Vd2 T cells were more predominant in the synovial fluid (Figure 5b) . Furthermore, many of the Vc9Vd2 T cells in the synovial fluid expressed HLA-DR (85.7560.96%) and CD86 (42.8565.9%) (Figure 5c and d) . These results suggested that a large number of the Vc9Vd2 T cells with potential antigen-presenting capability existed in the synovial fluid. The function of these cells may be similar to the function of APCs that can continuously activate CD4 1 T cells, which then leads to an intense immunoreaction in the joint and aggravates the immune injury. 
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Analyses of the IFN-c and IL-17 levels in the serum and synovial fluid of RA patients revealed that the levels of both cytokines were higher in the synovial fluid than in the serum (Figure 6a and b) . Moreover, compared with the synovial fluid from osteoarthritis patients, the synovial fluid from RA patients had higher titers of both IFN-c and IL-17, suggesting a more severe inflammatory reaction in the joints of the RA patients. Higher levels of IFN-c and IL-17 were detected in the SFMCs than in the PBMCs, which was probably because of the presence of a large number of TEM Vc9Vd2 T cells (Figure 6c and d) . These results indicated that cd T cells were an important source of inflammatory factors in the RA joints and that the cd T cells (particularly the Vc9Vd2 T cells) could secrete many cytokines that aggravated inflammation and immune disorder.
Analysis of the antigen-presenting capacity of cd T cells of RA patients It is known that HLA DRB1*04 is the major genotype in Chinese RA patients (47.37%) and that the EBVgp110 protein shares a common motif with the HLA DR4 subtype. 4 These facts suggest that EBV infection may be associated with the development of RA. We showed above that cd T cells can present both PPD (a large protein) and also TT (a small antigen). Thus, we synthesized three peptides: TTp (TT purified from natural resources has cellular toxicity), EBVgp110 and HLA-DR4. We explored the optimal reactive concentration of these antigens (data not shown) and then measured the immune response of PBMCs and SFMCs from RA patients to the established optimal concentration of TT, TTp, EBVgp110 and HLA-DR4. We used PBMCs from healthy donors as the controls. The PBMCs from the RA patients showed a stronger response to the antigens than the PBMCs from healthy donors. Moreover, the SFMCs responded more strongly to the viral antigen (EBVgp110) and the autoantigen (HLA-DR4) (Figure 7 ). These differences may be attributed to two factors. First, in the RA synovial fluid, the ab T cells were more active and there were more specific autoreactive CD4 1 T cells that had been previously activated, and thus, a secondary response could be quickly generated after these CD4 1 T cells were exposed to a viral antigen or autoantigen. Second, there were more cd T cells with the potential to present antigen in the synovial fluid, and they could recognize and present antigenic peptide to either the initial CD4 1 T cells or the autoreactive CD4 1 T cells more effectively and activate these cells to cause excessive immune responses. Figure 7 The responses of the PBMCs and SFMCs from RA patients to viral peptides and autoantigen peptides. Compared to the PBMCs from healthy donors, EBVgp110 and HLA-DR4 induced a more significant proliferation of PBMCs and SFMCs from RA patients. SFMCs had the strongest reactive efficacy (all experiments were repeated three times). cpm, counts per million; EBV, Epstein-Barr virus; PBMC, peripheral blood mononuclear cell; RA, rheumatoid arthritis; SFMC, synovial fluid mononuclear cell; TT, tetanus toxin; TTp, tetanus toxoid peptide.
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We also studied the optimal concentration of EBVgp110 and HLA-DR4 (data not shown) and the optimal ratio of cd T cells and CD4
T cells. At a constant CD4
1 T cell number, the CD4 1 T cells had the strongest proliferation at a 10 : 1 ratio of CD4
1 T cells to cd T cells. When purified cd T cells and B cells from RA patients were separately cocultured with CD4
1 T cells at various ratio (1 : 2.5, 1 : 5, 1 : 10, 1 : 20 and 1 : 40), the results indicated that the cd T cells from the RA patients can effectively present EBVgp110 and HLA-DR4, and the efficacy of presentation was significantly higher than that of B cells (Figure 8) . Therefore, we concluded that the TEM Vc9Vd2 T cells have a role as professional APCs in the pathogenicity of RA.
DISCUSSION
Epidemiological studies have revealed that 90% of people have a history of EBV infection and that EBV IgG-related antibodies can be detected, albeit at low levels, in the peripheral blood of most people. EBV can lurk in the human body for a long time after infection without producing any symptoms and can be activated to form a recurrent infection when the host immune function is compromised. We detected a high level of EBV-related antibodies and Dw4 antibodies (data not shown here) in the serum and synovial fluid of RA patients, suggesting a relationship between EBV infection and RA occurrence; the mechanisms of the immune disorder in RA patients are complex and involve many factors.
It is well known that individuals carrying particular MHC antigenic determinants are susceptible to specific diseases. For example, individuals carrying HLA-B27 are susceptible to ankylosing spondylitis, and those carrying HLA-DQ6 are susceptible to hypnolepsy. Hypothetically, this selective susceptibility is attributed to the high affinity between the MHC molecules and the pathogenic viral antigens (foreign or lurking in vivo), which results in recognition by autoreactive T cells in patients with these diseases. It was reported that 17.3% of the general population in China carry the HLA-DR4 gene compared to 43.8% of Chinese RA patients. As a subtype of HLA-II, HLA-Dw4 has a homologous sequence to EBVgp110; 4 therefore, the fact that RA patients with a HLA-DR4 genetic background had repetitive EBV infection history suggests a relationship between EBV infection and RA. Our study demonstrates that both EBVgp110 and HLA-DR4 Antigen-presenting effects of effector memory Vc9Vd2 T cells in RA CY Hu et al 252 peptide segments can induce the proliferation of T cells from the peripheral blood and synovial fluid of RA patients and that SFMCs have a stronger response to viral and autoantigen peptides. Furthermore, these findings explain that the occurrence of RA is focal in nature and is related to the specific genetic background and autoimmune disorders resulting from a viral infection.
More importantly, we found that the cd T cells in the peripheral blood from RA patients have a higher capacity to present EBVgp110 and HLA-DR4 than the B cells. According to the characteristics of cd T cells in the synovial fluid of RA patients, this higher capacity may be attributed to the large number of TEM Vc9Vd2 T cells (CD45RA 2 CD27 2 ) that could continuously activate CD4 1 T cells by presenting antigens to cause a sustained chronic inflammatory reaction in the joint. Furthermore, the TEM Vc9Vd2 T cells secrete various inflammatory factors (e.g., IFN-c and IL-17) and thus aggravate the inflammatory reaction.
Different results have been reported showing that the cd T cells were stimulated by inflammation independently of antigen at the affected joints. cd T cells have also been shown to produce enhanced IL-17, which exacerbated the arthritis in mice with collagen-induced arthritis but not in SKG mice, which are genetically prone to develop autoimmune arthritis, or in patients with RA. 28 Also, it was observed that in the arthritic joints, the collagen II-specific Th17 cells rather than the IL-17
1 cd T cells are the main effectors that trigger osteoclast-mediated joint destruction in an IL-23-dependent manner; 29 neither of these studies characterized the IL-17A-and Il-22-producting Vc2Vd2 T cells in detail nor examined the cytokine requirements for IL-17A production by human cd T cells. Thus, the potential role of cd T cells as sources of IL-17 and Il-22 in human immune responses is unclear. 30 However, cd T cells are often the major source of IL-17; their response can be very rapid during bacterial infections, and the response has been shown to be protective. However, IL-17-producing cd T cells have been found to exacerbate collagen-induced arthritis. Interestingly, some of the cd T cells produce IL-17 in response to IL-23 alone, even in naive animals, suggesting that the cd T cells are already differentiated and may develop differently than the CD4 1 ab Th17 cells. 13 Using IL-23R reporter mice, it has been shown that cd T cells were the first cells to respond to IL-23 during experimental autoimmune encephalomyelitis. Thus, IL-23, which by itself has no direct effect on regulatory T cells, is able to disarm regulatory T cell responses and promote antigen-specific effector T-cell responses via the activation of cd T cells. 31 This year, Silva-Santos B also showed that human Vc9Vd2 T cells can secrete the proinflammatory cytokine IL-17. 32 Additionally, cd T cells can affect the response of the B cells by direct cell-to-cell mediation. 33 Autoreactive B cells can maintain the activation of fibroblasts and also produce LT-b to participate in the formation of lymphoid tissues in the synovial tissue, 34 thus playing an important role in the development and progression of RA. Previous studies reported that cd T cells can be detected in the follicular germinal centers of B cells. 33 Recently, a new type of T cell (follicular helper cells, termed T FH ) that can help the activity of B cells has been identified. The T FH cells can effectively support the responses of B cells, including their proliferation, differentiation and production of antibodies. 35 Despite this progress, direct evidence of cd T cell-assisted Bcell activities during RA remains to be found.
In summary, cd T cells may have different biological functions in the development of RA through multiple pathways at various stages of the disorder. The exact mechanism requires more investigation.
